Latest Somaxon Pharmaceuticals (SOMX) Headlines
Ignyta Appoints Matthew Onaitis as General Counsel
Business Wire - Mon Feb 03, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Matthew Onaitis has been appointed to the newly created role of General Counsel and Secretary. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Trius Therapeutics, Inc., where he led the legal and compliance functions through Trius' acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Mr. Onaitis assisted Cubist with integration activities through December 2013. Prior to Trius, Mr. Onaitis was Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. from 2006 until Somaxon's acquisition by Pernix Therapeutics Holdings, Inc. in March 2013. Mr. Onaitis also previously served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.
CSX Corporation Announces Earnings Release and Fourth-Quarter Earnings Call
PR Newswire - Thu Dec 19, 9:57AM CST
CSX Corporation (NYSE: CSX) will release fourth-quarter and 2013 full-year financial and operating results on Wednesday, January 15, 2014, after the market close.
Royal Dutch Shell plc: Buyback of Own Shares
PR Newswire - Wed Dec 18, 11:12AM CST
Royal Dutch Shell plc (NYSE: RDS.A) (NYSE: RDS.B) announces that on 18 December, 2013 it purchased for cancellation 424,671 "B" Shares at a price of 2176.37 pence per share.
SANS' Tenth Annual Holiday Hacking Challenge is Now Live!
PR Newswire - Wed Dec 18, 10:26AM CST
SANS today announced its tenth annual free holiday hacking challenge. This annual year-end tradition helps teach in-demand cyber security skills for defending computers and networks in a fun and entertaining fashion using classic holiday themes. This year's challenge focuses on defending critical infrastructure systems, including power grids, water systems, and transportation infrastructures, all based on themes from the classic holiday movie, It's a Wonderful Life.
Personalized Medicine Partnering Terms and Agreements - 2013 Features Players such as Eli Lilly, GlaxoSmithKline and Wyeth
M2 - Mon Nov 18, 9:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/lldpqt/personalized) has announced the addition of the "Personalized Medicine Partnering Terms and Agreements" report to their offering. Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies. The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 1500 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Companies Mentioned: - Abbott Japan - Adnexus Therapeutics - Bayer - Boehringer Ingelheim - Cytokinetics - Daiichi Sankyo - Eli Lilly - Exelixis - Facet Biotechnology - GlaxoSmithKline - GTx - Hyperion Therapeutics - Ironwood Pharmaceuticals - Janssen Research & Development - KaloBios Pharmaceuticals - La Jolla Pharmaceutical - Merck KGaA - Ortho Biotech - Pfizer - PhotoMedex - Procter & Gamble - Schering-Plough - Somaxon Pharmaceuticals - Takeda Pharmaceutical - Ucyclyd Pharma - Valeant Pharmaceuticals - Watson Pharmaceuticals - Wyeth - Xenoport - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/ll...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Trius Appoints Matthew Onaitis as General Counsel
GlobeNewswire - Mon Jun 03, 3:00PM CDT
Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections, announced today Matthew Onaitis has been appointed to the newly created role of General Counsel and Secretary. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. where he led the legal, compliance and business development functions. Prior to his seven years at Somaxon, Mr. Onaitis served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.
Apricus Biosciences Appoints Richard W. Pascoe as Chief Executive Officer
GlobeNewswire - Mon Mar 18, 10:00AM CDT
Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) today announced the appointment of Richard W. Pascoe as Chief Executive Officer of the Company, effective March 18, 2013. Mr. Pascoe brings to Apricus Bio over 20 years of experience in corporate strategy as well as product development, sales and marketing in the biopharmaceutical industry, and has held positions of increasing responsibility at leading, innovative life science companies, including Somaxon Pharmaceuticals, ARIAD Pharmaceuticals and King Pharmaceuticals. In addition to his role as CEO, he has also joined the Company's Board of Directors. With Mr. Pascoe's appointment, Steve Martin, Interim Chief Executive Officer, will resume his responsibilities as Senior Vice President and Chief Financial Officer.
Pernix Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results
Business Wire - Mon Mar 18, 7:00AM CDT
--Completed the Acquisition of Somaxon Pharmaceuticals in March 2013
Pernix Therapeutics Holdings Inc acquires USD25m Somaxon Pharmaceuticals Inc, including insomnia drug Silenor
M2 - Thu Mar 07, 5:34AM CST
Pharmaceutical company Pernix Therapeutics Holdings Inc (NasdaqGM
TX) reported on Wednesday the completion of the acquisition of all of the common stock of Somaxon Pharmaceuticals Inc (NasdaqCM:SOMX) in a stock-for-stock transaction valued at USD25m.
Pernix Therapeutics Completes Acquisition of Somaxon Pharmaceuticals, Inc.
Business Wire - Wed Mar 06, 3:55PM CST
Pernix Therapeutics Holdings, Inc. ("Pernix") (NASDAQ: PTX) today announced the completion of its acquisition of Somaxon Pharmaceuticals, Inc. ("Somaxon") (NASDAQ: SOMX) following the approval of the transaction by stockholders of Somaxon at the special meeting held on March 6, 2013.
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Actavis
GlobeNewswire - Tue Feb 05, 3:30PM CST
Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Elizabeth LLC and Actavis Inc. to resolve pending patent litigation involving Silenor(R) 3 mg and 6 mg tablets.
PTX Reduces Sales Force, CFO Quits - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 28, 5:21PM CST
Pernix Therapeutics recently announced the integration of Hawthorn Pharmaceutical's sales forces with its own and a restructuring of the combined sales force.
Pernix Acquires Cypress and Hawthorn - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 04, 6:45PM CST
Pernix Therapeutics recently announced that it has completed the acquisition of Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals.
Somaxon Announces That Paladin Labs Has Received Approval of New Drug Submission for Silenor (R) in Canada
GlobeNewswire - Mon Dec 17, 3:35PM CST
Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) today announced that its licensee Paladin Labs Inc. (TSX LB) has received approval from Health Canada of Paladin's New Drug Submission (NDS) for Silenor (doxepin) for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal awakening and/or early morning awakenings.
Ignyta Appoints Matthew Onaitis as General Counsel
Business Wire - Mon Feb 03, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Matthew Onaitis has been appointed to the newly created role of General Counsel and Secretary. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Trius Therapeutics, Inc., where he led the legal and compliance functions through Trius' acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Mr. Onaitis assisted Cubist with integration activities through December 2013. Prior to Trius, Mr. Onaitis was Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. from 2006 until Somaxon's acquisition by Pernix Therapeutics Holdings, Inc. in March 2013. Mr. Onaitis also previously served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.
CSX Corporation Announces Earnings Release and Fourth-Quarter Earnings Call
PR Newswire - Thu Dec 19, 9:57AM CST
CSX Corporation (NYSE: CSX) will release fourth-quarter and 2013 full-year financial and operating results on Wednesday, January 15, 2014, after the market close.
Royal Dutch Shell plc: Buyback of Own Shares
PR Newswire - Wed Dec 18, 11:12AM CST
Royal Dutch Shell plc (NYSE: RDS.A) (NYSE: RDS.B) announces that on 18 December, 2013 it purchased for cancellation 424,671 "B" Shares at a price of 2176.37 pence per share.
SANS' Tenth Annual Holiday Hacking Challenge is Now Live!
PR Newswire - Wed Dec 18, 10:26AM CST
SANS today announced its tenth annual free holiday hacking challenge. This annual year-end tradition helps teach in-demand cyber security skills for defending computers and networks in a fun and entertaining fashion using classic holiday themes. This year's challenge focuses on defending critical infrastructure systems, including power grids, water systems, and transportation infrastructures, all based on themes from the classic holiday movie, It's a Wonderful Life.
Personalized Medicine Partnering Terms and Agreements - 2013 Features Players such as Eli Lilly, GlaxoSmithKline and Wyeth
M2 - Mon Nov 18, 9:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/lldpqt/personalized) has announced the addition of the "Personalized Medicine Partnering Terms and Agreements" report to their offering. Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies. The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 1500 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Companies Mentioned: - Abbott Japan - Adnexus Therapeutics - Bayer - Boehringer Ingelheim - Cytokinetics - Daiichi Sankyo - Eli Lilly - Exelixis - Facet Biotechnology - GlaxoSmithKline - GTx - Hyperion Therapeutics - Ironwood Pharmaceuticals - Janssen Research & Development - KaloBios Pharmaceuticals - La Jolla Pharmaceutical - Merck KGaA - Ortho Biotech - Pfizer - PhotoMedex - Procter & Gamble - Schering-Plough - Somaxon Pharmaceuticals - Takeda Pharmaceutical - Ucyclyd Pharma - Valeant Pharmaceuticals - Watson Pharmaceuticals - Wyeth - Xenoport - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/ll...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Trius Appoints Matthew Onaitis as General Counsel
GlobeNewswire - Mon Jun 03, 3:00PM CDT
Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections, announced today Matthew Onaitis has been appointed to the newly created role of General Counsel and Secretary. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. where he led the legal, compliance and business development functions. Prior to his seven years at Somaxon, Mr. Onaitis served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.
Apricus Biosciences Appoints Richard W. Pascoe as Chief Executive Officer
GlobeNewswire - Mon Mar 18, 10:00AM CDT
Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) today announced the appointment of Richard W. Pascoe as Chief Executive Officer of the Company, effective March 18, 2013. Mr. Pascoe brings to Apricus Bio over 20 years of experience in corporate strategy as well as product development, sales and marketing in the biopharmaceutical industry, and has held positions of increasing responsibility at leading, innovative life science companies, including Somaxon Pharmaceuticals, ARIAD Pharmaceuticals and King Pharmaceuticals. In addition to his role as CEO, he has also joined the Company's Board of Directors. With Mr. Pascoe's appointment, Steve Martin, Interim Chief Executive Officer, will resume his responsibilities as Senior Vice President and Chief Financial Officer.
Pernix Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results
Business Wire - Mon Mar 18, 7:00AM CDT
--Completed the Acquisition of Somaxon Pharmaceuticals in March 2013
Pernix Therapeutics Holdings Inc acquires USD25m Somaxon Pharmaceuticals Inc, including insomnia drug Silenor
M2 - Thu Mar 07, 5:34AM CST
Pharmaceutical company Pernix Therapeutics Holdings Inc (NasdaqGM
TX) reported on Wednesday the completion of the acquisition of all of the common stock of Somaxon Pharmaceuticals Inc (NasdaqCM:SOMX) in a stock-for-stock transaction valued at USD25m. Pernix Therapeutics Completes Acquisition of Somaxon Pharmaceuticals, Inc.
Business Wire - Wed Mar 06, 3:55PM CST
Pernix Therapeutics Holdings, Inc. ("Pernix") (NASDAQ: PTX) today announced the completion of its acquisition of Somaxon Pharmaceuticals, Inc. ("Somaxon") (NASDAQ: SOMX) following the approval of the transaction by stockholders of Somaxon at the special meeting held on March 6, 2013.
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Actavis
GlobeNewswire - Tue Feb 05, 3:30PM CST
Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Elizabeth LLC and Actavis Inc. to resolve pending patent litigation involving Silenor(R) 3 mg and 6 mg tablets.
PTX Reduces Sales Force, CFO Quits - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 28, 5:21PM CST
Pernix Therapeutics recently announced the integration of Hawthorn Pharmaceutical's sales forces with its own and a restructuring of the combined sales force.
Pernix Acquires Cypress and Hawthorn - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 04, 6:45PM CST
Pernix Therapeutics recently announced that it has completed the acquisition of Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals.
Somaxon Announces That Paladin Labs Has Received Approval of New Drug Submission for Silenor (R) in Canada
GlobeNewswire - Mon Dec 17, 3:35PM CST
Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) today announced that its licensee Paladin Labs Inc. (TSX
LB) has received approval from Health Canada of Paladin's New Drug Submission (NDS) for Silenor (doxepin) for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal awakening and/or early morning awakenings. 
